Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1686367

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1686367

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2025

PUBLISHED:
PAGES: 200 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 4490
PDF (Site License)
USD 6490
PDF (Enterprise License)
USD 8490

Add to Cart

Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics pertain to the treatment of a condition where the pancreas fails to produce adequate digestive enzymes necessary for the effective breakdown and absorption of nutrients from food within the small intestine. The role of EPI diagnostics and therapeutics is pivotal in the identification and management of exocrine pancreatic insufficiency, facilitating individuals with EPI in attaining improved nutrient absorption and overall well-being.

The primary forms of treatments encompassed within exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics comprise nutritional management, pancreatic enzyme replacement therapy (PERT), and lifestyle adjustments. Nutritional management is a specialized healthcare approach utilizing nutrition and diet to address various medical and health conditions. Diverse diagnostic techniques are employed, including blood tests, magnetic resonance imaging (MRI), endoscopic ultrasonography (EUS), and computerized tomography (CT) scanning. Various types of medications, both generic and branded, are utilized, and these are distributed through a range of channels such as direct tender, retail pharmacy, third-party distributor, and others. These are availed by a diverse array of end users including hospitals, specialty clinics, homecare, diagnostic centers, research and academic institutes, among others.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report is one of a series of new reports from The Business Research Company that provides exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market statistics, including exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry global market size, regional shares, competitors with a exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market share, detailed exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market segments, market trends and opportunities and any further data you may need to thrive in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics industry. This exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size has grown strongly in recent years. It will grow from $5.69 billion in 2024 to $6.17 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, rising global healthcare access.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size is expected to see strong growth in the next few years. It will grow to $8.32 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.

The growing prevalence of diabetes is anticipated to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Diabetes is a chronic condition characterized by elevated blood sugar levels (hyperglycemia), resulting from the body's inability to produce sufficient insulin or use the insulin effectively. EPI treatment, including pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption and support better glycemic control in individuals with both diabetes and EPI. For example, in June 2024, the National Health Service (NHS England) reported that the number of people diagnosed with pre-diabetes in 2023 increased to 3,615,330, an 18% rise from 3,065,825 in 2022. Among those under 40, pre-diabetes cases rose nearly 25%, from 173,166 in 2022 to 216,440 in 2023. This growing diabetic population is fueling the demand for EPI therapeutics and diagnostics.

The surge in cases of gastrointestinal disorders is projected to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the foreseeable future. Gastrointestinal disorders encompass a range of medical conditions affecting the digestive tract, including the organs responsible for digestion. Managing gastrointestinal diseases relies significantly on exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics, which rectify enzyme deficiencies and promote effective nutrient digestion. For instance, as of June 2023, Crohn's and Colitis Canada, a non-profit organization based in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting about 0.82% of the population. With the prevalence of IBD projected to persist, it is anticipated that approximately 470,000 Canadians will have IBD by 2035, roughly 1.1% of the population, or about 1 in every 91 individuals in the country. Consequently, the escalating incidence of gastrointestinal disorders is anticipated to be a driving force behind the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

Key players in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are increasingly forming strategic partnerships to integrate advanced technologies and broaden their market presence. A strategic partnership involves collaboration between two or more organizations, combining their resources, expertise, and efforts to reach shared objectives. For example, in February 2023, Codexis, Inc., a protein engineering firm based in the US, partnered with Nestle Health Science, a Swiss nutrition company, to announce the interim results of their Phase 1 clinical trial of CDX-7108, an investigational therapy for EPI. These promising results from the trial open the door for further research that could lead to improved treatment options for individuals affected by EPI.

In October 2022, DiaSorin SpA, an Italian biotechnology firm, acquired Luminex Corporation for $1.8 billion. This acquisition allows DiaSorin to bolster its presence in the U.S. market, expand its product portfolio, and establish long-term collaborations with biopharmaceutical companies. Luminex Corporation, based in the U.S., specializes in biological testing technologies, including those related to exocrine pancreatic insufficiency (EPI).

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market consists of revenues earned by entities by providing dietary interventions and bile acid replacement therapy (BAR). The market value includes the value of related goods sold by the service provider or included within the service offering. The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market also includes sales of Creon, Zenpep and Ultresa. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for exocrine pancreatic insufficiency (epi) therapeutics and diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Therapies: Nutritional Management; Pancreatic Enzyme Replacement Therapy (PERT); Lifestyle Modifications Approach
  • 2) By Diagnostics: Blood Tests; Magnetic Resonance Imaging (MRI); Endoscopic Ultra-Sonography (EUS); Computerized Tomography (CT) Scanning
  • 3) By Drug Type: Generic; Branded
  • 4) By Distribution Channel: Direct Tender; Retail Pharmacy ; Third-Party Distributor; Other Distribution Channels
  • 5) By End User: Hospitals; Specialty Clinics; Homecare; Diagnostic Center; Research And Academic Institutes; Other End Users
  • Subsegments:
  • 1) By Nutritional Management: Dietary Modifications; Nutritional Supplements
  • 2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations; Tablet Formulations; Powder Formulations
  • 3) By Lifestyle Modifications Approach: Weight Management; Physical Activity Recommendations; Smoking Cessation Programs
  • Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Janssen Pharmaceuticals Inc.; AbbVie Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.
Product Code: r28055

Table of Contents

1. Executive Summary

2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Characteristics

3. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends And Strategies

4. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth Rate Analysis
  • 5.4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Total Addressable Market (TAM)

6. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segmentation

  • 6.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Nutritional Management
  • Pancreatic Enzyme Replacement Therapy (PERT)
  • Lifestyle Modifications Approach
  • 6.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Blood Tests
  • Magnetic Resonance Imaging (MRI)
  • Endoscopic Ultra-Sonography (EUS)
  • Computerized Tomography (CT) Scanning
  • 6.3. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Generic
  • Branded
  • 6.4. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Direct Tender
  • Retail Pharmacy
  • Third-Party Distributor
  • Other Distribution Channels
  • 6.5. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Diagnostic Center
  • Research And Academic Institutes
  • Other End Users
  • 6.6. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Sub-Segmentation Of Nutritional Management, BY Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Dietary Modifications
  • Nutritional Supplement
  • 6.7. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Sub-Segmentation Of Pancreatic Enzyme Replacement Therapy (PERT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Capsule Formulations
  • Tablet Formulations
  • Powder Formulations
  • 6.8. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Sub-Segmentation Of Lifestyle Modifications Approach, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Weight Management
  • Physical Activity Recommendations
  • Smoking Cessation Programs

7. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Regional And Country Analysis

  • 7.1. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 8.1. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 9.1. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 9.2. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 10.1. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 11.1. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 11.2. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 12.1. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 13.1. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 14.1. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 14.2. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 15.1. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 15.2. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 16.1. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 17.1. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 18.1. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 19.1. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 20.1. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 21.1. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 21.2. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 22.1. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 23.1. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 23.2. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 24.1. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 24.2. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 25.1. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 25.2. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 26.1. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 26.2. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 27.1. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 28.1. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 28.2. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

  • 29.1. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
  • 29.2. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Therapies, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Landscape
  • 30.2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Janssen Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. AstraZeneca plc
  • 31.3. Abott Laboratories
  • 31.4. Medtronic plc
  • 31.5. Solvay S.A.
  • 31.6. Laboratory Corporation of America Holdings (Labcorp)
  • 31.7. Organon group of companies Metagenics LLC
  • 31.8. Allergan plc
  • 31.9. Chiesi Farmaceutici S.p.A.
  • 31.10. Codexis Inc.
  • 31.11. Nordmark Arzneimittel GmbH & Co. KG
  • 31.12. ChiRhoClin Inc.
  • 31.13. Digestive Care Inc.
  • 31.14. Alcresta Therapeutics Inc.
  • 31.15. Vivus Inc.

32. Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

34. Recent Developments In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market

35. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!